Of note, there were no effects of RAAS inhibitory drug treatments on circulating ACE2 activities (Fig. 2D, Table 2), left ventricular ACE2 activity (Fig. 2E, Table 2) or left ventricular ACE2 expression (Fig. 1F, Table 2) in end-stage heart failure patients. This evidence concerns the gene ACE2 and heart failure.